ARTICLE | Company News

Brazil nixes Soliris patent, says more could follow

April 20, 2018 9:21 PM UTC

A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said Soliris is only the first of "several other drugs" it plans to challenge in court.

Alexion markets Soliris to treat paroxysmal nocturnal hemoglobinuria in Brazil...

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 5 (C5)